EP0996631A1 - Analogues d'acide nucleique modifies - Google Patents

Analogues d'acide nucleique modifies

Info

Publication number
EP0996631A1
EP0996631A1 EP98966833A EP98966833A EP0996631A1 EP 0996631 A1 EP0996631 A1 EP 0996631A1 EP 98966833 A EP98966833 A EP 98966833A EP 98966833 A EP98966833 A EP 98966833A EP 0996631 A1 EP0996631 A1 EP 0996631A1
Authority
EP
European Patent Office
Prior art keywords
group
probe
nucleic acid
nucleic acids
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98966833A
Other languages
German (de)
English (en)
Inventor
Frank Bergmann
Herbert Von Der Eltz
Rupert Herrmann
Stefanie KÖHLER
Volker SCHLÜTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dako Denmark ApS
Original Assignee
Roche Diagnostics GmbH
Dako AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH, Dako AS filed Critical Roche Diagnostics GmbH
Publication of EP0996631A1 publication Critical patent/EP0996631A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to a method for the detection of a target containing base sequence in a sample using one or more special hybridization probes, a solid support to which this hybridization probe is bound, and the use of negative charges in partially charged hybridization probes to avoid non-specific binding and to increase the selectivity in binding reactions.
  • nucleic acids in samples has gained considerable importance in analytics in recent years. The validity of such tests has proven to be particularly useful in healthcare, where the detection of pathogens, such as viruses and bacteria, in and outside the body, as well as physical conditions, such as genetic predispositions to diseases, is required. This is all the more true since it has been possible to specifically amplify base sequences from the nucleic acids to be detected, for example with the polymerase chain reaction (PCR, US-A-4,683,202).
  • PCR polymerase chain reaction
  • the samples in which the presence of the nucleic acid to be detected are suspected are brought into contact with a hybridization probe, the probe being selected so that it has a base sequence which is essentially complementary to a base sequence of the nucleic acid to be detected. The fact that the probe hybridizes with the nucleic acid is taken as an indication of the presence of the nucleic acid.
  • hybridization probes were used as hybridization probes.
  • the introduction of automated nucleotide syntheses made it possible to produce short nucleic acids (oligonucleotides) in high purity and with a defined, freely selectable base sequence.
  • the introduction of chemically labeled mononucleoside phosphoramidites made it easy to introduce labein for non-hazardous, non-radioactive detection.
  • hybridization probes have also been found which surprisingly bind very tightly to nucleic acids, although they do not or do not mix the sugar-phosphate backbone that is typical for nucleic acids together with contain other basic units (e.g.
  • the object of the present invention is to partially or completely avoid the disadvantages of the prior art, in particular to utilize the higher affinity of PNA probes while avoiding non-specific bindings and high blank value signals. Additional suppression of amplicon re-hybridization is also an advantage of the present invention (use of low salt conditions).
  • the present invention therefore relates to a molecule which can be hybridized with nucleic acids and has a backbone of monomer units linked linearly to one another, at least one of the monomer units being a non-nucleoside unit. which contains an acid function with a pK a of less than 3.0.
  • the invention also relates to monomers for the production of these molecules. Methods for the detection of nucleic acids using these molecules and the use of acid functions, preferably with a pK_ of less than 3.0, in probes to avoid non-specific binding of the probes to non-complementary base sequences and to solid supports, to increase the selectivity in binding reactions, in primers as well as in molecules for transfection.
  • molecules which hybridize with nucleic acids and which contain non-nucleoside units are known. In principle, they can be divided into molecules that contain only (non-natural) non-nucleoside units and molecules that contain both non-nucleoside and (naturally occurring) nucleoside units. - All these molecules have in common that they are composed of monomer units. These are linearly linked with one another in such a way that an oligomer with a continuous backbone results, to which ligands are bound at substantially uniform intervals.
  • these ligands In order for the oligomer to be able to hybridize with nucleic acids, some of these ligands (generally more than 6 ligands) must be able to recognize and bind nucleobases of the nucleic acid via hydrogen bonding.
  • Such ligands are, for example, the naturally occurring nucleobases, such as A, G, C, T and U, but also artificial heterocycles. such as 7-deazapurine or pseudopyrimidine.
  • these molecules can contain other ligands that do not necessarily contribute to binding with the nucleic acid.
  • Such ligands are, for example, groups which can be used to detect or separate the molecules in methods for the detection of the nucleic acid.
  • Such ligands can attach to the nucleobases.
  • ligands are described, for example, in WO 92/20703, WO 95/14708 (metal complexes), DE 197 12 530.1 and WO 95/16202 (peptides).
  • the subject matter of the present invention differs from that described therein in that at least one of the monomer units used there contains a function with a pK a of less than 3.0.
  • EP-A-0 672 677 describes a synthesis of nucleic acid analogs in which nucleosidic and non-nucleosidic monomer units are mixed with one another.
  • the subject matter of the present invention differs from the molecules described therein in that one of the non-nucleoside monomer units contains an acid function with a pK of less than 3.0.
  • a monomer unit is preferably understood to mean a unit which is part of the above-mentioned oligomer and which contains at most one nucleobase. These units preferably contain only those parts of the molecule which were already present in the monomers used for the synthesis of the oligomers. As a rule, the oligomer is between 6 and 100, preferably 8 and 30, monomer units long.
  • the calculation of the length of the basic unit of each monomer is based on the fact that the geometric length between the connection points of the individual monomers is essentially the same and preferably with the connection points of the monomers. from which the oligomer is made coincides.
  • the length of a backbone unit extends from the carbonyl group of one end of the monomer unit to the amino end of the same monomer unit which is bonded to the subsequent carbonyl group of the next monomer unit.
  • the length of a basic framework unit defined in this way is preferably between 4 and 8. particularly preferably 6 atoms.
  • the modified monomer unit can in principle be any, ie also the last, nucleobase-containing monomer unit of the molecule. However, the modified monomer unit is particularly preferably not the last base-containing monomer unit of the oligomer. The modified monomer unit is particularly preferably within the inner third of the total length of the molecule.
  • the molecule hybridizing with nucleic acids can in principle contain as many modified monomer units as there are monomer units. However, it is preferred that less than half of the monomer units represent a modified monomer unit. The remaining monomer units are preferably not negatively charged; they are preferably neutral.
  • the discrimination between nucleic acids with a different base sequence in one or more positions is favored by the fact that the molecule is selected so that the modified monomer unit is installed approximately in the middle of the molecule, specifically to the nucleic acid to be detected, but not with a nucleic acid to be discriminated therefrom is complementary in this position (mismatch).
  • an acid function is understood to mean a chemical group which is covalently bound to the non-nucleoside unit. In the form bound to the non-nucleoside unit, this group preferably has a pK of less than 3.0.
  • 2- or polybasic acids are preferred.
  • Preferred acid functions are selected from the group of inorganic acids, in particular the groups of sulfonic acids, phosphonic acids or phosphoric acids or their salts.
  • a sulfonic acid residue is preferably a group of the formula -SO 3 H.
  • a phosphonic acid residue is preferably understood to mean a residue of the formula -PO 3 H 2 .
  • Phosphoric acids contain the group -OP (OH) 2 O.
  • the acid function is preferably not involved in the covalent bond between two monomer units.
  • the acid function is preferably bound to a carbon atom of the backbone, which is not the first in addition to a hetero atom (O, P, S or N) used for the linkage with the next monomer.
  • the acid function can either directly or via a spacer A 'with the basic unit of the monomer unit, preferably one atom of the continuous chain of atoms in the backbone, e.g. B. a C atom. be connected.
  • the acid function together with the spacer A ' is also referred to below as a group R containing an acid function with a pK a of less than 3.0.
  • the spacer A ' connects an atom of a series of linearly consecutive atoms of the basic structure with an atom of the acid function. In principle, these spacers can be between 1 and 20 atoms long.
  • a 2 is a substituted or unsubstituted alkylene, alkynylene or alkenylene
  • R 6 is independently hydrogen. Acyl or alkyl,
  • a and c independently of one another a number from 0 to 2
  • b is a number from 1 to 10
  • d is a number from 1 to 4
  • the spacer can be installed in either of the two possible orientations.
  • Alkyl Acyl, alkylene. Alkinylene and alkenylene radicals in the definition of A 2 and R 6 preferably have 1 to 3 carbon atoms. Substituents can be chosen, for example, from the group hydroxyl, halogen (e.g. Cl, Br or F) or amino.
  • the molecule according to the invention is preferably an oligomer hybridizing with nucleic acids and containing at least one non-nucleoside monomer unit of the formula I.
  • L is selected from the group hydrogen, hydroxyl, (C, - C 4 ) - alkanoyl, nucleobase-binding group, (C 6 -C 14 ) aromatics, heterocycles with nitrogen, oxygen or / and sulfur atoms, intercalators and reporter groups,
  • A is a spacer with a length of 1 to 3 atoms.
  • x is a number between 0 and 3
  • B is a basic unit with a length of between 4 and 8 atoms
  • R is a group containing an acid function with a pK_ of less than 3.0
  • a preferred alkanoyl group is the acetyl group.
  • Nucleobases are to be understood as the naturally occurring bases A, C, G, T and U.
  • a nucleobase-binding group is a group which can form with such a nucleobase via interactions specific to hydrogen bonds. In addition to the (complementary) natural nucleobases, this also includes unnatural nucleobases, such as. B. 7-deazaguanosine or pseudopyrimidines.
  • Aromatics can be both substituted and unsubstituted. Particularly suitable substituents are hydroxyl, C 1 -C 2 -alkoxy or amino. Preferred aromatics are the phenyl, pyrenyl and naphthyl radicals.
  • Heterocycles are cyclic compounds that contain one or more heteroatoms. selected from the group consisting of O, N and S, which can be non-aromatic or aromatic. They too can be substituted by the radicals mentioned for aromatics.
  • heterocycles are the pyridyl radical and the piperidyl radical.
  • Intercalators are molecules that can be inserted into the base-base interaction of neighboring bases, e.g. B. acridine.
  • a reporter group can be used to detect or immobilize the molecule. Immunologically active compounds and biospecific interactions from binding molecules from reporter groups are particularly suitable.
  • a particularly preferred group of reporter groups are the markings or labels.
  • the electrochemiluminescent ruthenium bispyridyl complexes are particularly preferred here.
  • L is particularly preferably bonded via a spacer A to a nitrogen atom, particularly preferably to an amine nitrogen atom, in B.
  • the group R is likewise preferably bound to the backbone unit, but not directly to the nitrogen atom to which L is bound.
  • Particularly preferred molecules have at least one monomer unit of the formula II
  • E 'and F' independently CO, CS. SO. SO 2 or NR 1 ,
  • R is selected from the group hydrogen and (C, -C 3 ) - alkyl
  • N is an amine nitrogen atom.
  • C and D are independently selected from the group (CR 2 R 3 ) n and CR 2 R 3 CR 4 R 5
  • R 2 , R ⁇ R 4 and R 5 are independently selected from the group
  • n is a number between 1 and 4.
  • At least one of the radicals R 2 -R 3 or R -R 5 is a group R.
  • the invention also relates to a molecule of the formula IV
  • E and F independently COOX, CSOX. SO 2 X. SO, X or NR 1 Y,
  • R 1 is selected from the group consisting of hydrogen and (C, -C 3 ) -alkyl
  • X is selected from the group consisting of hydrogen, the protective groups and the activation groups,
  • Y is selected from the group hydrogen and protective group
  • N is an amine nitrogen atom
  • C and D are independently selected from the group (CR 2 R 3 ) ⁇ and CR 2 R 3 CR 4 R 5
  • R 2 , R 3 , R 4 and R 5 are independently selected from the group
  • n is a number between 1 and 4.
  • these molecules can be used for the synthesis of the oligomers according to the invention.
  • Particularly preferred are those molecules in which one of the radicals E and F is a protected amino or carboxylic acid function and the other either a reactive group, such as a carboxylic acid or primary amino group, or a corresponding activated derivative, e.g. B. an active ester.
  • An activation group is, for example, 1-oxybenzotriazole.
  • the acid function is preferably protected with the aid of a protective group, preferably in the form of an ester which can be cleaved without the oligomer being fragmented.
  • Such protective groups are, for example, benzyl and ⁇ -cyanoethyl.
  • synthesis methods known, for example, from chemical oligonucleotide synthesis or the synthesis of peptide nucleic acids can be used analogously to the synthesis of the oligomers according to the invention or those used according to the invention.
  • a particularly suitable monomer is shown in Figure 1 (compound 3). It is a derivative of the amino acid homoserine. This compound is at the amino end of the backbone monomer unit with a t-butyloxycarbonyl (Boc) protective group on any exocyclic amino groups of the base with a benzyloxycarbonyl (Z) group and at the hydroxyl group of the homoserine by replacing the hydrogen with a di- Benzyl ester protected phosphate group.
  • Boc t-butyloxycarbonyl
  • FIG. 1 also shows a compound (4) in which the amino group of the basic unit is protected with a monomethoxytrityl protective group and the exocyclic amino functions of the base are protected with an acyl protective group (benzoyl, isobutyryl).
  • the homoserine hydroxyl group is esterified with a di- ⁇ -cyanoethyl-protected phosphate residue.
  • Compound 5 shows the corresponding deprotected monomer unit built into the oligomer.
  • FIG. 1 also shows the corresponding monomer 1 based on serine as the amino acid and the deprotected monomer unit 2.
  • compounds 6. 7, 8 and 9 the phosphonates and sulfonates based on homoserine are shown.
  • the spacers between the acid function (PO 4 2 “ , PO 3 2 ' and SO 3 " ) and the carbon atom of the linear backbone chain preferably follow the formula (CH 2 ) n , n taking values from 1 to 6, preferably 2 to 4.
  • the invention also relates to a method for detecting the presence or absence of a nucleic acid in a sample, which is suspected. that it contains one or more non-detectable nucleic acids (nucleic acid (s) to be discriminated), the base sequence of which differs from the base sequence of the nucleic acid in one or more positions, comprising the steps of contacting a probe which contains a base sequence which is to be detected , but is not complementary to the other nucleic acids, and determining whether binding of the probe to a base sequence complementary to the base sequence has taken place, characterized in that the probe is a nucleic acid hybridizable molecule with a backbone of linearly linked monomer units, at least one of the monomer units is a non-nucleoside unit. which contains an acid function with a pK a of less than 3.0 is used.
  • the method according to the invention is a special embodiment of the so-called hybridization tests.
  • the basic features of the specialist on the Are known in the field of nucleic acid diagnostics. Insofar as experimental details are not set out below, the entire content is "nucleic acid hybridization". Edited by BD Harnes and SJ Higgins, IRL Press, 1986. B. in Chapters 1 (Hybridization Strategy), 3 (Quantitative Analysis of Solution Hybridization) and 4 (Quantitative Filter Hybridization), Current Protocols in Molecular Biology, Ed. FM Ausubel et al. J. Wiley and Son. 1987, and Molecular Cloning, Ed. J. Sambrook et al. CSH, 1989.
  • a probe is generally understood to mean a nucleic acid-binding molecule which has been made distinguishable from natural nucleic acids by attaching a chemical group.
  • the chemical group can be an immobilizable group, on the one hand, or a label.
  • This probe contains a base sequence which contains a base sequence which is complementary to a sequence of the nucleic acid to be detected, but not to a sequence of the other nucleic acids which are not to be detected.
  • This sequence is preferably longer than 10 bases.
  • the sequence is preferably continuous and uninterrupted.
  • the length of the sequence is preferably 10 or more bases, particularly preferably 15 or more bases.
  • the probe can also contain further bases which do not influence the discriminatory properties of the probe, since they do not lead to a stronger binding of the probe to a non-detectable nucleic acid than to the one to be detected. In general, this is ensured if these bases are not complementary to a base sequence which is located directly next to a potential binding sequence for the probe on a non-detectable nucleic acid.
  • additional bases can be used, for example, to specifically recognize the probe itself via a nucleotide sequence, e.g. B. for use as a universal detection probe.
  • a label in the sense of the present invention consists of a directly or indirectly detectable group L.
  • Directly detectable groups are, for example, radioactive ( 32 P), colored or fluorescent groups.
  • Indirectly detectable groups are, for example, immunologically or enzymatically active compounds, such as antibodies, antigens. Haptens or enzymes or enzymatically active partial enzymes. These are detected in a subsequent reaction or reaction sequence. Haptens are particularly preferred. because the oligomers marked with them Detection via a subsequent reaction with a labeled antibody against the hapten can easily be made.
  • the invention is particularly effective for lipophilic labels such as biotin. Fluorescein. Pyrenyl or ruthenium organic complexes.
  • An immobilizable group is understood to be a chemical residue which can be used to bind the probe to a solid phase. Suitable for this are therefore both activatable residues (e.g. photoactivatable), but also partners of a specific binding pair, such as receptors and associated ligands, partners of an immunological reaction, such as. B. Haptens. Antigens or antibodies, or vitamins or receptors for these vitamins. Haptens or biotin and its derivatives are particularly preferred as the immobilizable group. Biotin is particularly preferred.
  • the solid phase, to which the probe can be bound by means of the immobilizable group has a corresponding binding partner or a corresponding reactivity. In the case of biotin, the solid phase can therefore have a coating of streptavidin.
  • An analyte nucleic acid is understood to mean the nucleic acid which is the aim of the detection. These are to be understood as meaning nucleic acids of any origin, for example viroid nucleic acids. viral. bacterial or cellular origin. They can be in solution, suspension, but also fixed to solids or in cell-containing media. Cell smears, fixed cells, tissue sections or fixed organisms are present. The nucleic acids are preferably in solution (in vitro).
  • the reaction sequence is usually started by making the analyte nucleic acid available with appropriate reagents. Changes in the pH (alkaline), heat, repetition of extreme temperature changes (freezing / thawing), changes in the physiological growth conditions (osmotic pressure), exposure to detergents, chaotropic salts or enzymes (e.g. proteases, lipases), contribute alone or in combination to the release of the nucleic acids.
  • Denaturation of nucleic acids means separation of nucleic acid double strands into single strands.
  • a specific detection is understood to mean a method by which, if desired, certain nucleic acids can also be selectively discriminated in the presence of others.
  • Nucleic acids can be detected. However, it is also possible to detect a group of nucleic acids with a partially identical or similar nucleotide sequence. To detect double-stranded nucleic acids, either of the two complementary strands can be included.
  • the specific sequence of the probe is preferred to a length of more than 10, preferably more than 15 bases to more than 90, preferably more than 95 and particularly preferably 100% complementary to a sequence of the same number of continuously successive bases of the nucleic acid to be detected.
  • the present invention has particularly good effects for sequences which are particularly rich in purine, ie contain more than 50% purines. It is particularly preferred for sequences which contain 4 or more purines in a continuous row. z. B. G included.
  • the monomer unit modified according to the invention is preferably within this homopurine range.
  • a nucleic acid or nucleic acid sequence that is essentially complementary to a nucleic acid means nucleic acids or sequences that can hybridize with the corresponding nucleic acid, the nucleotide sequence of which in the hybridizing region is either exactly complementary to the other nucleic acid or differs in a few bases from the exactly complementary nucleic acid.
  • the specificity depends on both the degree of complementarity and the hybridization conditions.
  • Two bases are usually complementary to one another if they can form base pairings with one another, which preferably follow the Watson-Crick rule or the Hoogsteen base pairing.
  • the complementarity condition refers to two or more base sequences with directly adjacent bases with a length of 10 or more bases.
  • Exactly complementary means 100% complementary: if there are differences, these should be less than 10%, preferably less than 5%, of the bases within the hybridizing region. The differences must of course be chosen so that they do not significantly impair the specificity of the test for the nucleic acid to be detected.
  • the nucleic acid to be detected can be the analyte nucleic acid itself. However, it can also be a nucleic acid which was prepared from the analyte nucleic acid by pretreatment in the sample liquid.
  • nucleic acid to be detected has a size of at least 40 bp.
  • the nucleic acid to be detected is preferably the product of an upstream specific or non-specific nucleic acid amplification.
  • nucleic acid amplification methods are known for example from EP-A-0 201 184, EP-A-0 237 362, EP-A-0 329 822, EP-A-0 320 308 or WO 88/10315.
  • the analyte nucleic acid serves as a template nucleic acid for the production of the nucleic acid that is ultimately to be detected.
  • the nucleic acid can also be a nucleic acid produced by cloning and in vivo propagation.
  • a method for detecting a specific virus, e.g. B. HGV, in a body fluid (z. B. serum) contain as a first step the lysis of the virus envelope.
  • Methods for the lysis of cell walls are known to the person skilled in the art.
  • the lysis can be carried out by treatment with alkali hydroxide solutions.
  • auxiliary substances e.g. B. detergents is possible.
  • viruses which are only present in low concentrations in body fluids eg hepatitis C virus
  • in vitro nucleic acid amplification eg via the polymerase chain reaction or the other amplification methods mentioned above ).
  • a large number of nucleic acids are formed with the analyte nucleic acid as template nucleic acid, which are then detected in the method according to the invention.
  • the method according to the invention could also be preceded by several steps.
  • bacterial samples are disrupted if necessary after in vivo multiplication of the bacteria under conditions which bring about the lysis of the bacterial cell wall (eg proteinases. Alkali).
  • an in vitro amplification of the bacterial analyte nucleic acids can follow.
  • the result of the various pretreatments is a sample liquid which contains nucleic acids in solution and which may contain the reagents used in the preparatory steps and possibly destroyed cell components.
  • the probes according to the invention show an inverted image compared to DNA probes.
  • DNA probes With DNA probes, the signal dynamics and sensitivity increase with increasing salt concentration.
  • PNA probes modified according to the invention it has been shown that the preferred concentration of salt (NaCl) is between 0 and 150 mM.
  • FIG. 2 A comparison of probes according to the invention against DNA probes is shown in FIG. 2.
  • the first diagram shows the influence of sodium chloride concentration on the sensitivity of an HGV test using a ruthenium complex-labeled DNA probe at different salt concentrations.
  • the second diagram shows the same experiment with a PNA probe according to the invention with the same sequence, the ruthenium complex being bound to the PNA backbone via two glutamine residues. and the backbone also contains two glutamine residues. It can be seen that the salt dependency for the DNA probe is different compared to the PNA probe, even though the probe contains negative charges. Especially at low salt concentrations, at which the renaturation of the amplicon double strand is suppressed. the signal dynamics and sensitivity are optimal when using partially negatively charged PNA probes in contrast to DNA probes.
  • the third diagram shows the salt dependency of a probe that contains two lysine residues (positive charges) in the backbone.
  • the signal dynamics and sensitivity are hardly dependent on salt, but the blank value signals are greatly increased, especially at low salt concentrations.
  • the salt dependence is an unmodified one. shown in the backbone neutral PNA probe with two glutamic acid residues as a linker to the ruthenium complex.
  • the optimal NaCl concentration is 50 mM.
  • the blank signal is significantly increased.
  • the label on the probe is used, whose presence in the complex of nucleic acid to be detected and the probe is used to indicate the presence of the nucleic acid to be detected. This is preferably done after having separated any excess probe from the hybrid. This can be done, for example, by trapping the hybrid with the help of a solid-phase capture probe.
  • the liquid phase is removed from the solid phase (e.g. from the vessel, the porous material or the pelleted beads). The solid phase can then be washed with a suitable buffer.
  • the amount of the hybrid bound to the solid phase from the nucleic acid, detection probe and capture probe to be detected can be determined in a manner known in principle, e.g. B. in the manner of a sandwich hybridization process.
  • the hybrid is implemented with the detection probe according to the invention, which is complementary to a different nucleotide sequence of the nucleic acid to be detected than the capture probe, and hybridizes with it.
  • This forms a hybrid of the detection probe, the nucleic acid to be detected and the capture probe on the solid phase.
  • the detection probe is preferably added to the sample together with the capture probe with the hybridization solution.
  • the amount of label is determined fluorometrically.
  • the detectable group is indirectly detectable z.
  • the hybrid is preferably reacted with a labeled antibody against the hapten, as described analogously in EP-A-0 324 474.
  • the label on the antibody can be, for example, a color or fluorescent label or, preferably, an enzyme label, such as ⁇ -galactosidase, alkaline phosphatase or peroxidase.
  • enzyme labeling the amount of nucleic acid is monitored via the mostly photometric chemiluminometric or fluorometric monitoring of a reaction of the enzyme with a chromogenic. chemiluminogenic or fluorogenic substrate measured.
  • the measurement signal is a measure of the amount of originally present nucleic acid to be detected and thus possibly of organisms to be detected.
  • the non-nucleosidic differs particularly preferably. modified basic scaffold unit at a position in which the nucleic acid to be detected differs from one of the non-detectable nucleic acid present in the sample, from at least one of the two adjacent basic scaffold units, which is not intended to mean the base.
  • modified basic scaffold unit at a position in which the nucleic acid to be detected differs from one of the non-detectable nucleic acid present in the sample, from at least one of the two adjacent basic scaffold units, which is not intended to mean the base.
  • This can be realized, for example, in that the adjacent basic unit does not have a negative charge or does not have the acid function, or that it is based on another monomer unit. e.g. another amino acid, based in the linear part of the backbone.
  • the sample which contains the nucleic acid to be detected in addition to other nucleic acids is treated in such a way that the nucleic acid to be detected is released from cells which may be present and any proteins adhering to it are denatured. This can be followed by isolation of the nucleic acids from this mixture.
  • the nucleic acids freed from any inhibitors of the amplification can then be amplified, e.g. B. be subjected to a PCR. It is preferred to use one of the primers labeled with an immobilizable group. After completion of the amplification, the amplificates are detected by hybridization with a probe according to the invention.
  • the probe is preferably selected such that it hybridizes with the amplificates in a region between the hybridization positions of the primers.
  • the detection takes place after immobilization of the amplificates and hybridization with the probe.
  • magnetic particles can preferably be used which recognize the immobilizable group of the amplificates.
  • the reagent solution with the excess probes is preferably removed before the detection. l ⁇
  • the oligomers according to the invention are particularly suitable for the detection of mutations, alleles or polymorphisms as well as for the typing or subtyping of microorganisms.
  • the oligomers preferably contain both such an acid function within the binding region of the oligomer with the nucleic acid to be detected and also a negative charge outside the binding region. e.g. at the end (s) or in the linker between the binding area and the marking.
  • oligomers in which less than 80. preferably less than 50 and particularly preferably less than 40%, but at least one of the bases is attached to a negatively charged basic unit, e.g. B. one by an acid function with a pK a of less than 5.0, preferably less than 3.0. modified, bound, bind significantly less non-specifically to nucleic acids (e.g. length markers) that are relatively unrelated in their sequence. You therefore avoid unspecific binding in reactions to bind the probe to complementary base sequences (Table 1).
  • a negatively charged basic unit e.g. B. one by an acid function with a pK a of less than 5.0, preferably less than 3.0. modified
  • relatively unrelated nucleic acids nucleic acids which do not contain a continuous and uninterrupted sequence of more than 10, preferably more than 15 bases, which are more than 50% complementary to an equally long uninterrupted and continuous sequence of bases of the probe. Blank values, especially for electrochemiluminescence measurements. are reduced.
  • the oligomers according to the invention are distinguished by an increased selectivity in binding reactions. In contrast to oligomers. where a positive charge was attached to the backbone (e.g. T-Lys-containing PNAs) and neutral PNAs, significantly lower blank value signals were obtained, especially with decreasing salt concentration (Table 1).
  • the oligomers according to the invention are also less prone to non-specific binding to solid phases, e.g.
  • hydrophilic surfaces such as particles or vessels coated with streptavidin.
  • non-specific binding is understood to mean a binding that is not based on base-base interaction.
  • Neutral and very particularly negatively charged surfaces are particularly suitable for the use of the oligomers according to the invention.
  • PNAs with a glutamic acid-containing backbone are described. Such oligomers can also be used to avoid unspecific binding non-complementary nucleic acids or solid phases can be used. 18mers and 14mers were used as probes in comparative experiments. The probes differ as shown in Table 2.
  • the amplificate of an HBV test is used. This amplificate has no complementarity to the probe used.
  • no nucleic acids are added, so that only the non-specific binding of the probe to the surface of the magnetic particle is measured.
  • Cases 1 and 2 also show. that unspecific binding to nucleic acids, which are not similar to the sequence complementary to the probe sequence, also contribute to the blank signal. This applies both to the primers that are inevitably contained in the reaction mixture and to controls, such as standards. Here, too, a reduction in the blank value is determined by using negatively charged probes. This contribution was even completely eliminated in the present experiment.
  • Case 4 shows that in the presence of amplicons. which, for example, can be attributed to the simultaneous amplification of a further analyte in the reaction mixture, a considerable blank value signal is found which can be practically eliminated by using negatively charged probes.
  • the reaction preferably takes place in a plastic vessel.
  • vessels which are normally used as sample storage vessels in conventional automatic analyzers. Examples are vessels made of polystyrene, polyethylene or luran.
  • the vessel in which the treatment takes place is preferably already in an automatic analyzer, particularly preferably on a sample rotor, which allows a sampling device to access individual sample vessels located on the rotor.
  • an automatic analyzer is described for example in EP-A-0 361 830.
  • These oligomers are also suitable. in which less than 80%, preferably less than 50%, but at least one of the bases are bound to negatively charged basic framework units, particularly preferably the oligomers according to the invention. excellent as a primer.
  • Oligomers according to the invention are particularly suitable as primers. which has an extendable hydroxyl group, e.g. B. Nucleosides. and the next monomer unit is a non-nucleoside unit which has an acid function with a pK a of less than 5.0. preferably contains less than 3.0.
  • primers which has an extendable hydroxyl group, e.g. B. Nucleosides. and the next monomer unit is a non-nucleoside unit which has an acid function with a pK a of less than 5.0. preferably contains less than 3.0.
  • oligomers can. in which less than 80%, preferably less than 50%, but at least one of the bases are bound to negatively charged basic framework units, particularly preferably the oligomers according to the invention compared to unmodified, neutral PNAs, e.g. B. with so-called transfection reagents, for. B. DOSPER or DOTAP. are better introduced into cells.
  • transfection reagents are for nucleic acids from Bio Forum 6/96. Page 264.
  • the oligomers according to the invention can therefore be used well in antisense technology or as gene probes.
  • the negative charges can in principle be distributed in the molecule.
  • the negative charges in the form of a group described above with a pK a of less than 5.0 (3.0) to a base-bearing basic unit, but it is also possible to bind them outside the sequence of base-containing basic units, e.g. . B. at one or both ends of the oligomers or to the nucleobase itself (eg DE-19712530). It has been found that in this case the negative charges advantageously have additional, non-base-bearing bases. scaffolding units.
  • the label or the immobilizable group also being located on one or more of these additional basic unit units.
  • the additional basic framework units also act as a linker between the label and the base sequence specific for the nucleic acid to be detected. Those probes in which both negative charges are present within the base sequence and in the linker appear to be particularly advantageous.
  • the aqueous phase is extracted three times with 200 ml of ethyl acetate.
  • the combined organic phases are then dried over Na : SO. It is filtered off and rotated in.
  • the residue is dissolved in 100 ml of benzene and mixed with 5.80 g (30.5 mmol) of p-toluenesulfonic acid.
  • the mixture is boiled under reflux for 1 hour, then the solution is concentrated to a volume of about 20 ml and the product is crystallized by slowly adding diethyl ether.
  • the solid is filtered off and recrystallized from methanol / diethyl ether. After drying under high vacuum 1 1.1 g (77%) of the product are obtained as p-toluenesulfonic acid salt in the form of colorless crystals.
  • the organic phase is then washed successively with 150 ml of saturated sodium bicarbonate solution, semi-saturated potassium hydrogen sulfate solution and and saturated sodium chloride solution, then over Na ; SO 4 dried. It is filtered off and rotated in. The residue is purified on a silica gel column using ethyl acetate / hexane 2: 1 as the elution system. The product is then crystallized using ethyl acetate / diethyl ether. Yield: 3.6 g (57%).
  • the synthesis was carried out on an ABI 433 A peptide synthesizer from Applied Biosystems with modified software (T. Koch et al., J. Peptide Res. 1997, 49, 80-88). The syntheses were carried out on a 5 ⁇ mol scale in a 3 ml reaction vessel, a smaller measuring loop (150 ⁇ l) was used.
  • the monomer components (PNA components: Boc-T-OH, Boc-A (Z) -OH, Boc-C (Z) -OH and Boc-G (Z) -OH, available from Perseptive Biosystems, Boc-T-Glu (Bzl) -OH prepared according to Example 1; amino acid derivatives: Boc-Glu (OBzl) -OH, available from Novabiochem AG; Ru (ruthenium) (bpy) 3 -COOH from Boehringer Mannheim) were in NMP dissolved and injected into individual cartridges (140 ⁇ l, 0.26M).
  • the MBHA carrier material (Novabiochem AG) derivatized with Boc-Gly (Novabiochem AG) is filled into the 3 ml reaction vessel and attached to the synthesizer.
  • Trifluoroacetic acid / m-cresol 95 5 (2 x 180 sec); Bottle position 2) is used to split off the Boc protecting group.
  • the PNA is split off from the resin and the protective groups in a manual step outside the device in a special, lockable glass frit.
  • the resin is first washed with trifluoroacetic acid, then shaken for 2 hours with 2 ml of trifluoromethanesulfonic acid / trifluoroacetic acid / m-cresol 2: 8: 1.
  • the separation solution is sucked into a centrifuge glass. It is washed with 1 ml of trifluoroacetic acid and the PNA is precipitated with diethyl ether (approx. 10 ml). The precipitate is separated from the supernatant solution after centrifugation. Then it is washed twice with diethyl ether.
  • the PNA was analyzed by means of an analytical RP18-HPLC (DeltaPak. Waters, 5 ⁇ , 125 ⁇ 4 mm) with a water / acetonitrile / 0.1% trifluoroacetic acid gradient at 60 ° C.
  • the PNA was purified by preparative RP18-HPLC (Polygosil C-18 / Macherey-Nagel, 5 ⁇ , 250 x 20 mm) with a water / acetonitrile / 0.1% trifluoroacetic acid gradient at 60 ° C. until chromatographic uniformity.
  • the analysis of the purified PNA is carried out with MALDITOF-MS.
  • a comparison of a detection probe according to the invention with unmodified or otherwise modified PNA-Ru probes using an identical sequence illustrates the advantages of the invention.
  • a DNA probe was used as a reference; the experiment was carried out using the example of HGV. a) amplification
  • plasmids were used which were amplified by means of PCR.
  • the following primers were used to prepare the specific amplificates:
  • HGV primer sequences coding-strand:
  • HBV primer sequences coding-strand:
  • HBV 10 ng plasmid pJCP (HGV: nucleotides 1-550 cloned in pGEM3z; Stratagene: HBV:
  • the amplification was carried out with the following temperature profile on a Perkin Elmer Cycler 9600:
  • the PCR product was purified after the end of the reaction using the High pure PCR template purification kit (BM Order No. 1 796 828).
  • the PCR product in the specified dilutions was used to evaluate the various PNA-Ru probes.
  • the detection was carried out with the aid of electrochemilinescence (ECL) on an Elecsys® 1010 (Boehringer Mannheim GmbH).
  • ECL electrochemilinescence
  • the reaction temperature for all steps is 37 ° C.
  • 10 ⁇ l of sample are first mixed with 35 ⁇ l of denaturing reagent and incubated for 5 minutes.
  • 120 ⁇ l of the probe solution 50 ng / ml in hybridization buffer
  • 35 ⁇ l of streptavidin-coated magnetic microparticles are added to the reaction mixture and incubated again for 10 minutes.
  • the hybrids bio-labeled HGV strand with Ru-labeled detection probe
  • the samples are transferred to the measuring cell and the microparticles are bound there by a magnet.
  • the chemiluminescence then takes place in the measuring cell.
  • the Ru complex When catalysed by TPA, the Ru complex emits flashes of light. the number of which are determined in the measuring cell.
  • the chemistry for electrocheminoluminescence is in J. Electrochem. Soc. 137: 3127-3131.
  • A. DNA probe A. DNA probe:
  • the probes were tested in the experiment described above, the result is shown in Table 4.
  • the first part (4a) shows the mean value of the signals from a double determination
  • the second (4b) shows the ratio of the signal to the background signal.
  • the sensitivity does not deteriorate when the salt concentration in the hybridization buffer is low.
  • the competition reaction between unlabeled strand from the PCR reaction with the detection probe becomes lower Salt concentration shifted towards the probe, which enables a large dynamic measuring range with very good sensitivity.
  • the modified probe according to the invention allows a particularly large dynamic measuring range to be covered, which is particularly important for quantitative detection
  • HGV PCR product 1 5 424834 666051 1184377 332695 1570831 945988 1084935 247646 1687111 463255
  • HGV PCR product 1 5 483.31 748.37 841.18 268.52 16.72 65.95 18.27 9.91 101.76 111.04
  • Example 3 A length standard marked with biotin (corresponding to Cat.No. 1062590, only 5 'biotin marked) was used as sample material.
  • the concentration of the stock solution: 1 ⁇ l corresponds to 250 ng DNA.
  • A. DNA probe A. DNA probe:
  • HGV PCR product 1 5 246843 424834 666051 1211085 1184377 332695 1331089 823696 2802342 1274087
  • Length marker VI 1 100 739 743 900 1075 1266 1836 9225 10845 25825 7712
  • HBV PCR product 1 5 834 856 904 921 1123 1225
  • HGV PCR product 1 5 280.5 483.3 748.4 1005.9 841.2 268.5 431.2 185.9 499.8 661.9
  • Length marker VI 1 100 0.8 0.8 1.0 0.9 0.9 1.5 3.0 2.4 4.6 4.0
  • HBV PCR product 1 5 0.9 1.0 1.0 0.8 0.8 1.0
  • HGV was determined with the aid of a DNA probe (diagram 1), a positively charged PNA probe (diagram 3) and two negatively charged probes (diagrams 2 and 4).
  • the salt content (0; 50; 150; 200; 300; 625 mM) was varied. The measurement results are shown graphically in FIG. The results are discussed in the description.

Abstract

Des oligomères comportant au moins une unité non nucléoside qui contient une fonction acide avec un pKa inférieur à 3,0, s'utilisent notamment comme sondes de mise en évidence de la présence d'acides nucléiques, les interactions non spécifiques étant abaissées comparativement à des oligomères non modifiés. Même à de faibles concentrations en sel du tampon d'hybridation, on peut obtenir une dynamique du signal et une sensibilité élevées en cas de signal réduit d'essai à blanc. Ces oligomères s'utilisent également comme amorces pour des réactions d'allongement à l'aide de polymérases et pour des opérations de transfection.
EP98966833A 1997-12-23 1998-12-18 Analogues d'acide nucleique modifies Withdrawn EP0996631A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19757516A DE19757516A1 (de) 1997-12-23 1997-12-23 Modifizierte Nukleinsäureanaloga
DE19757516 1997-12-23
PCT/EP1998/008317 WO1999033867A2 (fr) 1997-12-23 1998-12-18 Analogues d'acide nucleique modifies

Publications (1)

Publication Number Publication Date
EP0996631A1 true EP0996631A1 (fr) 2000-05-03

Family

ID=7853170

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98966833A Withdrawn EP0996631A1 (fr) 1997-12-23 1998-12-18 Analogues d'acide nucleique modifies

Country Status (3)

Country Link
EP (1) EP0996631A1 (fr)
DE (1) DE19757516A1 (fr)
WO (1) WO1999033867A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019136A1 (de) * 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
DE10019135A1 (de) 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
EP1251183A3 (fr) * 2001-04-18 2003-12-10 Exiqon A/S Des sondes assistantes supérieures pour la détéction d'une séquence cible utilisant une sonde de capture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2284208A (en) * 1993-11-25 1995-05-31 Pna Diagnostics As Nucleic acid analogues with a chelating functionality for metal ions
PT804456E (pt) * 1994-10-06 2003-01-31 Peter Eigil Nielsen Conjugados de acidos nucleicos dos peptidos
AU5856596A (en) * 1995-05-10 1996-11-29 Isis Pharmaceuticals, Inc. Inhibition of transcription factor-mediated transcriptional activation by oligomer strand invasion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9933867A2 *

Also Published As

Publication number Publication date
WO1999033867A2 (fr) 1999-07-08
WO1999033867A3 (fr) 1999-09-02
DE19757516A1 (de) 1999-06-24

Similar Documents

Publication Publication Date Title
EP0324474B1 (fr) Procédé pour détecter des acides nucléiques
DE69233630T2 (de) Sätze von HIV-Sonden zur Verwendung in Sandwich-Hydridisierungsassays in Lösungsphase
DE60310532T2 (de) Bestimmung von nukleinsäuren
EP0212951B1 (fr) Acides nucléiques marqués
DE69432919T2 (de) Verfahren für den Nachweis spezifischer Polynukleotiden
EP0379559B1 (fr) Procede et reactifs de detection de sequences d'acides nucleiques
DE69432419T2 (de) Ein elektrochemiluminescenter nachweis von nukleinsäuren auf basis der selbsttragenden sequenzreplikation
DE60214840T2 (de) Verfahren zur markierung und fragmentierung von dns
EP0608737B1 (fr) Nucléotides qui contiennent sulfocumarin et leur utilisation dans les méthodes de détection des acides nucléiques
DE69725611T2 (de) Nicht-Nukleotid verknüpfende Reagentien
EP0688784B1 (fr) Dérivés d'oligonucléotides modifiés en position 3'
JPH02503146A (ja) ヌクレオチドプローブ用非ヌクレオチド連結試薬
AU3274500A (en) Detection of mutations in genes by specific lna primers
EP0628568A2 (fr) Procédé d'immobilsation d'acides nucléiques
EP0829542A1 (fr) Méthode d'amplification des acides nucléiques
EP0523557B1 (fr) Immobilisation des acides nucléiques
EP1831246B1 (fr) Sonde pour detecter la presence d'acides nucleiques
EP0742286A2 (fr) Détection quantitative d'acides nucléiques
WO1990008838A1 (fr) Marquage d'acides nucleiques a l'aide de marqueurs fluorescents
DE19548680A1 (de) Verfahren zum quantitativen Nachweis von spezifischen Nukleinsäuresequenzen
EP0996631A1 (fr) Analogues d'acide nucleique modifies
DE60123056T2 (de) Basenanaloge
WO1992022671A1 (fr) Dosage de polynucleotides a l'aide de sites de clivage pouvant etre selectionnes
DE69919778T2 (de) Optisch aktive DNS-Sonde mit Phosphonsäurediester-Bindung
DD265429A1 (de) Verfahren zur nichtradioaktiven markierung von polynukleotiden

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DAKO A/S

17Q First examination report despatched

Effective date: 20011015

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020425